Hematology
An Introduction to Hematology
The field of haematology is far-reaching, encompassing many conditions of the blood and blood-forming organs, including anaemia, bleeding and coagulation disorders, sickle cell disease, congenital immunodeficiency diseases, transfusion medicine and haematopoietic stem cell transplantation. There continue to be many obstacles to gene therapy but ultimately this approach holds promise in inherited blood disorders. In addition, novel anticoagulant therapies, multiplexed sensing platforms and the application of artificial intelligence in diagnosis and monitoring are proving valuable in clotting disorders.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
The AIEOP-BFM ALL 2017 trial represents one of the clearest demonstrations to date that frontline immunotherapy can outperform and out-safeguard conventional chemotherapy in pediatric ALL. Beyond its immediate implications for high-risk disease, the study may provide the framework for broader treatment redesign across ALL risk groups, with future trials now focused on how far chemotherapy exposure can be safely reduced while preserving—and potentially improving—long-term cure. In this exclusive Q&A, Prof Martin Schrappe suggests this may be only the beginning of chemotherapy de-escalation in childhood ALL.
For almost two decades, R-CHOP has remained the established frontline standard for DLBCL, yet approximately 40% of patients are not cured with first-line therapy. At EHA 2026, Prof Georg Lenz presented new phase 3 data from the frontMIND study suggesting that this long-standing backbone may now be open to improvement. The study showed that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival (PFS) in previously untreated patients with high-risk DLBCL and high-grade B-cell lymphoma (HGBL), marking one of the first positive frontline intensification trials in this setting in recent years.
Late-breaking data from the phase 3 SENTRY trial show that selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naïve myelofibrosis, with rapid and sustained responses and an early signal for overall survival benefit. While symptom improvement was comparable to ruxolitinib alone, exploratory biomarker findings suggest potential disease-modifying activity, positioning the combination as a possible new frontline strategy.
The European Hematology Association (EHA) 2026 Congress brought together the global hematology community to unveil the latest practice-shaping advances in hematological malignancies and blood disorders. From plenary and late-breaking trial results to prestigious award winners, novel therapeutics, translational science and emerging technologies, the meeting delivered a vast volume of data. In this expert-led round-up, leading specialists distil the most important data and key takeaways from across each disease area, offering an essential guide to the studies set to shape the future of hematology.
These infographics review CLL management, from initial diagnosis and staging through treatment initiation and discontinuation, and assessment of patient risks.
See who the oncology community selected as the rising stars of 2026!
In this Future Leaders interview, Margaret Wheless reflects on the mentors who shaped her career, the fulfillment she finds in patient care and teaching, and the importance of empathy, collaboration, and intentional mentorship for emerging oncologists.
The first primary microangiopathic haemolytic anaemia was identified as thrombotic thrombocytopenic purpura (TTP) by Dr Moschowitz in 1924. At that time, the classic pentad of clinical features, still used today, included fever, erythrocyte fragmentation, thrombocytopenia, kidney injury and neurologic injury.1 It ...
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted rest impacts physician health in both the short and long term, safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
